Literature DB >> 33948369

The PVT1/miR-612/CENP-H/CDK1 axis promotes malignant progression of advanced endometrial cancer.

Rong Cong1, Fanfei Kong1, Jian Ma1, Qing Li1, Hui Yang1, Xiaoxin Ma1.   

Abstract

Our previous study introduced the oncogenic role of the long non-coding RNA plasmacytoma variant translocation 1 (PVT1) in endometrial cancer (EC). In this study, we aimed to construct a PVT1-centered competing endogenous RNA (ceRNA) network to outline a regulatory axis that might promote the malignant progression of advanced EC. Raw Uterine Corpus Endometrial Carcinoma (UCEC) datasets were collected from The Cancer Genome Atlas (TCGA) database and used for construction of the PVT1-centered ceRNA network. The ceRNA binding sites were established using dual-luciferase assays. FISH assays displayed the co-location of PVT1 and miR-612 in EC cells. Immunohistochemistry, in situ hybridization, qRT-PCR, and western blots were used to assess the expression of miR-612 and CENP-H in EC tissues, and their functions on biological behaviours were examined by a series of in vitro and in vivo assays. Molecule interactions were illustrated by co-transfection assays. The bioinformatics analysis showed that PVT1/miR-612/CENP-H/CDK1 axis played a vital role in the malignant progression of advanced EC. MiR-612 was downregulated in EC tissues and acted as a tumour suppressor to inhibit cell proliferation, migration, invasion, and promote cell apoptosis. CENP-H was found overexpressed in EC tissues, and the expression level was correlated to diagnosis and prognosis of EC. Hyperactivated CENP-H promoted cell proliferation, migration, invasion, and inhibited cell apoptosis. Overexpressed CENP-H prevented the anti-tumour effects observed with upregulated miR-612; knockdown of miR-612 also suppressed the anti-tumour effects of downregulated PVT1. Knockdown of PVT1 together with upregulated miR-612 exerted the strongest anti-tumour effects in nude mice. These effects were mediated by CDK1 through modulation of the Akt/mTOR signaling pathway. In conclusion, the PVT1/miR-612/CENP-H/CDK1 axis promoted the malignant progression of advanced EC and could serve as a promising target for potential treatments. AJCR
Copyright © 2021.

Entities:  

Keywords:  CDK1; CENP-H; PVT1; ceRNA; endometrial cancer; lncRNA; miR-612

Year:  2021        PMID: 33948369      PMCID: PMC8085881     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  5 in total

Review 1.  The functions of lncRNAs in the HPV-negative cervical cancer compared with HPV-positive cervical cancer.

Authors:  Yi Liu; Hejing Liu; Bo Sheng; Shuya Pan; Zhi-Wei Wang; Xueqiong Zhu
Journal:  Apoptosis       Date:  2022-08-18       Impact factor: 5.561

2.  Effect of LncPVT1/miR-20a-5p on Lipid Metabolism and Insulin Resistance in NAFLD.

Authors:  Han Zhang; Qinghui Niu; Kun Liang; Xuesen Li; Jing Jiang; Cheng Bian
Journal:  Diabetes Metab Syndr Obes       Date:  2021-11-23       Impact factor: 3.168

3.  Hypoxia-induced PVT1 promotes lung cancer chemoresistance to cisplatin by autophagy via PVT1/miR-140-3p/ATG5 axis.

Authors:  Jiying Wang; Zhiyi Dong; Zhaoying Sheng; Yong Cai
Journal:  Cell Death Discov       Date:  2022-03-07

4.  Systematic Pan-Cancer Analysis Identifies CDK1 as an Immunological and Prognostic Biomarker.

Authors:  Yaqi Yang; Qin Liu; Xiyuan Guo; Qing Yuan; Siji Nian; Pengyuan Kang; Zixi Xu; Lin Li; Yingchun Ye
Journal:  J Oncol       Date:  2022-08-31       Impact factor: 4.501

5.  A novel chromatin regulator-related immune checkpoint related gene prognostic signature and potential candidate drugs for endometrial cancer patients.

Authors:  Zesi Liu; Hongxia Yang; Ziyu Chen; Chunli Jing
Journal:  Hereditas       Date:  2022-10-18       Impact factor: 2.595

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.